Publication

Baricitinib in COVID-19: a coming-of-age from artificial intelligence to reducing mortality

Downloadable Content

Persistent URL
Last modified
  • 05/14/2025
Type of Material
Authors
    Puja Mehta, University College LondonBoghuma Titanji, Emory University
Language
  • English
Date
  • 2022-07-30
Publisher
  • Elsevier
Publication Version
Copyright Statement
  • © 2022 Elsevier Ltd. All rights reserved.
Final Published Version (URL)
Title of Journal or Parent Work
Volume
  • 400
Issue
  • 10349
Start Page
  • 338
End Page
  • 339
Supplemental Material (URL)
Abstract
  • Immunomodulatory therapies targeting excessive host immune responses,1 vaccination, and immunity from natural infection have changed the course of the COVID-19 pandemic. However, the rapid emergence of SARS-CoV-2 variants has stymied progress towards ending the pandemic. An unmet need remains for accessible therapies that reduce mortality. In The Lancet, the RECOVERY Collaborative Group assessed the use of baricitinib, a Janus kinase (JAK) inhibitor, for the treatment of patients hospitalised with COVID-19, in the randomised, controlled, open-label platform trial (Randomised Evaluation of COVID-19 Therapy [RECOVERY]).2 The potential use of baricitinib in COVID-19 was first identified from an artificial-intelligence-enabled drug discovery algorithm.3 Baricitinib can suppress multiple cytokine-signalling pathways simultaneously and impede viral propagation through inhibition of numb-associated kinases important for clarthrin-mediated endocytosis.4
Author Notes
  • PM is a Medical Research Council (MRC)-GlaxoSmithKline EMINENT clinical training fellow with project funding unrelated to the topic of this Comment and receives co-funding from the National Institute for Health Research (NIHR) University College London Hospitals (UCLH) Biomedical Research Centre. PM reports consultancy fees from SOBI, AbbVie, UCB, Lilly, Boehringer Ingelheim, and EUSA Pharma all unrelated to the topic of this Comment. BKT receives grant funding from Emory CFAR-P30AI050509 and consultancy fees from the non-profit organisation CRITICA, all unrelated to the topic discussed here. We thank Grant Schulert (Cincinnati Children's Hospital, USA) for his useful input on use of baricitinib in paediatric populations.
Keywords
Research Categories
  • Health Sciences, Immunology
  • Biology, Virology

Tools

Relations

In Collection:

Items

Thumbnail Title File Description Date Uploaded Visibility Actions
file details Publication File - vzhx2.pdf Primary Content 2025-05-13 Public Download